Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lun… (NCT07384897) | Clinical Trial Compass
RecruitingNot Applicable
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Belgium425 participantsStarted 2025-02-17
Plain-language summary
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Who can participate
Age range
80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of lung cancer
* Presence of precancerous lung lesions
* Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment
* Control group: individuals without known lung disease
* Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
* Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected
Exclusion Criteria:
* Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent)
* Acute infection at the time of inclusion
* Refusal or inability to provide informed consent (or assent, when applicable)
* Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression free survival
Timeframe: Throughout the entire study, approximately during 7 years